GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Cash Flow from Operations

Australian Clinical Labs (ASX:ACL) Cash Flow from Operations : A$153.9 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Dec. 2023, Australian Clinical Labs's Cash Receipts from Operating Activities was A$346.0 Mil. Its Cash Payments was A$-262.8 Mil. Its Dividends Paid was A$0.0 Mil. Its Dividends Received was A$0.0 Mil. Its Interest Paid was A$-8.0 Mil. Its Interest Received was A$0.2 Mil. Its Taxes Refund Paid was A$-2.0 Mil. And its Cash Flow from Others was A$-0.0 Mil. In all, Australian Clinical Labs's Cash Flow from Operations for the six months ended in Dec. 2023 was A$73.5 Mil.


Australian Clinical Labs Cash Flow from Operations Historical Data

The historical data trend for Australian Clinical Labs's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Cash Flow from Operations Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23
Cash Flow from Operations
- 153.86 284.09 143.68

Australian Clinical Labs Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial 182.38 101.71 63.27 80.41 73.53

Australian Clinical Labs Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Australian Clinical Labs's Cash Flow from Operations for the fiscal year that ended in Jun. 2023 is calculated as:

Australian Clinical Labs's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$153.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Australian Clinical Labs  (ASX:ACL) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Australian Clinical Labs's cash receipts from operating activities for the six months ended in Dec. 2023 was A$346.0 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Australian Clinical Labs's cash payments for the six months ended in Dec. 2023 was A$-262.8 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Australian Clinical Labs's cash payments for the six months ended in Dec. 2023 was A$0.0 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Australian Clinical Labs's cash payments for the six months ended in Dec. 2023 was A$0.0 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Australian Clinical Labs's cash payments for the six months ended in Dec. 2023 was A$-8.0 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Australian Clinical Labs's cash payments for the six months ended in Dec. 2023 was A$0.2 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Australian Clinical Labs's cash payments for the six months ended in Dec. 2023 was A$-2.0 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Australian Clinical Labs's cash flow from others for the six months ended in Dec. 2023 was A$-0.0 Mil.


Australian Clinical Labs Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Australian Clinical Labs (ASX:ACL) Business Description

Traded in Other Exchanges
N/A
Address
1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines